Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kowa, Nissan Chemical Win US Patent Case over Livalo Crystal Form
January 10, 2019
- Meiji to Set Up JV with Canadian Firm to Develop Novel β-lactamase Inhibitor
January 9, 2019
- Eisai Recalls Azeptin after It Fails Dissolution Tests
January 9, 2019
- Investigator-Initiated US PII Study to Start for Telomelysin/Keytruda Combo: Oncolys
January 9, 2019
- Kyorin Introduces Voluntarily Recall of Desalex
January 9, 2019
- Fycompa Designated for Priority Review in China
January 9, 2019
- Takeda Completes £46 Billion Shire Acquisition
January 8, 2019
- Kyowa Kirin Files Burosumab in Japan
January 8, 2019
- Takeda Revving Up Collaboration Efforts on I/O Front
January 8, 2019
- Daiichi Sankyo Grabs Europe Rights to 1st-in-Class Cholesterol Drug
January 8, 2019
- Fujifilm to Make 10 Billion Yen Capital Investment in Bio CDMO Business
January 8, 2019
- Kaken Licenses Systemic Sclerosis Treatment from Corbus in Japan
January 8, 2019
- J-TEC’s Cell Sheet JACE Approved for Epidermolysis Bullosa
January 8, 2019
- Sumitomo Dainippon Corrects Announcement on US Latuda Settlement
January 7, 2019
- JCR Completes Patient Enrolment in Japan PIII Study for Hunter Syndrome Treatment
January 7, 2019
- Nipro to Strive for Stable Supply of Stemirac, 1st Stem Cell Therapy for Spinal Cord Injury
January 7, 2019
- Can Daiichi Sankyo Take Big Leap in Oncology with 3 FDA Nods in FY2019?
January 4, 2019
- Japan Gives Conditional OK to 1st Stem Cell Therapy for Spinal Cord Injury
December 28, 2018
- Reata Developing Sakigake Designated DKD Drug for Alport Syndrome in Japan
December 28, 2018
- Kyorin, Hebrew University Link Arms in Respiratory Drug Development
December 28, 2018
ページ
International regulators are increasingly moving away from comparative efficacy studies (CES) in biosimilar development — long considered a default requirement…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…